CAR-T Study – A Milestone in Autoimmune Therapy
We are proud to have successfully treated the first SLE patient in Australia with a cutting-edge CAR-T cell therapy. Although this study is now closed to recruitment, it represents a major advancement in the treatment of autoimmune conditions.
- Monash Nephrology-currently recruiting Lupus Nephritis patients – Phase II CAR-T study
- Monash Rheumatology will be recruiting SLE patients later this year – Phase II CAR-T study
Learn more about the ASSURO study, which is testing an investigational drug when given to people with Rheumatoid Arthritis or Lupus.
– follow the clinical trials link for more details.
Coming in mid-August 2026-a Phase III study for Lupus skin disease
- DLE/SCLE (with or without SLE)-(CLASI>8)
- ACLE with SLE-(CLASI>8)
This study is for 6 months, an oral agent with the option of open-label extension
– follow the clinical trials link for more details.
New Phase III Sjögren’s Study – Coming in 2027
Details to come
No longer coming in @late 2026: allogeneic CAR-T Study
This particular study will no longer be activated in Australia.
Please click the link to the pdf outlining all current clinical trials – updated regularly with new trials.
